CDG logo

Acorda Therapeutics MUN:CDG Stock Report

Last Price

€0.79

Market Cap

€277.6k

7D

0%

1Y

-93.3%

Updated

02 Jul, 2024

Data

Company Financials

Acorda Therapeutics, Inc.

MUN:CDG Stock Report

Market Cap: €277.6k

CDG Stock Overview

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.

CDG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Acorda Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acorda Therapeutics
Historical stock prices
Current Share PriceUS$0.79
52 Week HighUS$15.90
52 Week LowUS$0.79
Beta1.65
11 Month Change0%
3 Month Change-53.82%
1 Year Change-93.28%
33 Year Changen/a
5 Year Changen/a
Change since IPO-91.74%

Recent News & Updates

Recent updates

Shareholder Returns

CDGDE BiotechsDE Market
7D0%-3.0%-0.1%
1Y-93.3%-19.4%2.3%

Return vs Industry: CDG underperformed the German Biotechs industry which returned -19.4% over the past year.

Return vs Market: CDG underperformed the German Market which returned 2.3% over the past year.

Price Volatility

Is CDG's price volatile compared to industry and market?
CDG volatility
CDG Average Weekly Movementn/a
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: CDG's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine CDG's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995102Ron Cohenwww.acorda.com

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. Fundamentals Summary

How do Acorda Therapeutics's earnings and revenue compare to its market cap?
CDG fundamental statistics
Market cap€277.62k
Earnings (TTM)-€245.33m
Revenue (TTM)€107.72m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CDG income statement (TTM)
RevenueUS$115.66m
Cost of RevenueUS$20.48m
Gross ProfitUS$95.19m
Other ExpensesUS$358.61m
Earnings-US$263.42m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-212.08
Gross Margin82.30%
Net Profit Margin-227.75%
Debt/Equity Ratio-103.1%

How did CDG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.